Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q99972: Variant p.Asn57Ser

Myocilin
Gene: MYOC
Feedback?
Variant information Variant position: help 57 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Asparagine (N) to Serine (S) at position 57 (N57S, p.Asn57Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (N) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help Loss of higher molecular weight isoform. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 57 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 504 The length of the canonical sequence.
Location on the sequence: help LRKANDQSGRCQYTFSVASP N ESSCPEQSQAMSVIHNLQRD The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         LRKANDQSGRC-------------------QYTFSVASPNESSCPEQSQAMSVI--------------HNLQRD

                              LRKANDRSGRC-------------------QYIFSVASPNE

Mouse                         FRKANDRSGRC-------------------QYTFTVASPNE

Rat                           FRKANDRSGRC-------------------QYTFTVASPSE

Bovine                        FQKANDRSGRC-------------------QYTFSVASPSE

Rabbit                        LRKANDRSGRC-------------------QYTFSVASPSE

Cat                           LRKANDRSGRC-------------------QYTFSVASPNE

Slime mold                    -SMINEKENQCVIISGESGAGKTEAAKKIMQYIADVSGERG

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 33 – 504 Myocilin
Chain 33 – 226 Myocilin, N-terminal fragment
Glycosylation 57 – 57 N-linked (GlcNAc...) asparagine



Literature citations
Characterization of rabbit myocilin: implications for human myocilin glycosylation and signal peptide usage.
Shepard A.R.; Jacobson N.; Sui R.; Steely H.T.; Lotery A.J.; Stone E.M.; Clark A.F.;
BMC Genet. 4:5-5(2003)
Cited for: CHARACTERIZATION OF VARIANT SER-57; GLYCOSYLATION; TISSUE SPECIFICITY; SUBCELLULAR LOCATION; Myocilin analysis by DHPLC in French POAG patients: increased prevalence of Q368X mutation.
Melki R.; Belmouden A.; Brezin A.; Garchon H.-J.;
Hum. Mutat. 22:179-179(2003)
Cited for: VARIANTS GLC1A ARG-367; ILE-438; LYS-480 AND PHE-499; VARIANTS SER-57; LYS-76 AND ARG-398;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.